Bruce Woda to Prognosis
This is a "connection" page, showing publications Bruce Woda has written about Prognosis.
Connection Strength
0.342
-
Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014 Nov; 25(11):2211-2217.
Score: 0.081
-
Patel SA, Khedr S, Gordon CD, Nuvvula S, Littman N, Woda B, Hutchinson L, Li S, Xie Y, Selove W, Cerny J, Gerber JM. Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point-of-care p53 immunohistochemistry. Cancer. 2025 Jul 01; 131(13):e35950.
Score: 0.043
-
Xing W, Dresser K, Zhang R, Evens AM, Yu H, Woda BA, Chen BJ. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget. 2016 Sep 13; 7(37):59976-59986.
Score: 0.023
-
Gong Y, Woda BA, Jiang Z. Oncofetal protein IMP3, a new cancer biomarker. Adv Anat Pathol. 2014 May; 21(3):191-200.
Score: 0.020
-
Shi M, Xiao R, Woda BA, Yu H. Five important advances in hematopathology. Arch Pathol Lab Med. 2014 Mar; 138(3):410-9.
Score: 0.020
-
Lu D, Yang X, Jiang NY, Woda BA, Liu Q, Dresser K, Mercurio AM, Rock KL, Jiang Z. IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer. Am J Surg Pathol. 2011 Nov; 35(11):1638-45.
Score: 0.017
-
Kurian EM, Caporelli ML, Baker S, Woda B, Cosar EF, Hutchinson L. Cervista HR and HPV 16/18 assays vs hybrid capture 2 assay: outcome comparison in women with negative cervical cytology. Am J Clin Pathol. 2011 Nov; 136(5):808-16.
Score: 0.017
-
Hao S, Smith TW, Chu PG, Liu Q, Ok CY, Woda BA, Lu D, Lin P, Wang SA, Dresser K, Rock KL, Jiang Z. The oncofetal protein IMP3: a novel molecular marker to predict aggressive meningioma. Arch Pathol Lab Med. 2011 Aug; 135(8):1032-6.
Score: 0.016
-
Tang G, Wang SA, Menon M, Dresser K, Woda BA, Hao S. High-level CD34 expression on megakaryocytes independently predicts an adverse outcome in patients with myelodysplastic syndromes. Leuk Res. 2011 Jun; 35(6):766-70.
Score: 0.016
-
Chang TY, Jaffray J, Woda B, Newburger PE, Usmani GN. Hemophagocytic lymphohistiocytosis with MUNC13-4 gene mutation or reduced natural killer cell function prior to onset of childhood leukemia. Pediatr Blood Cancer. 2011 May; 56(5):856-8.
Score: 0.016
-
Wang SA, Tang G, Fadare O, Hao S, Raza A, Woda BA, Hasserjian RP. Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification. Mod Pathol. 2008 Nov; 21(11):1394-402.
Score: 0.013
-
Jiang NY, Woda BA, Banner BF, Whalen GF, Dresser KA, Lu D. Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2008 Jul; 17(7):1648-52.
Score: 0.013
-
Sitnikova L, Mendese G, Liu Q, Woda BA, Lu D, Dresser K, Mohanty S, Rock KL, Jiang Z. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res. 2008 Mar 15; 14(6):1701-6.
Score: 0.013
-
Yue G, Hao S, Fadare O, Baker S, Pozdnyakova O, Galili N, Woda BA, Raza A, Wang SA. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. Leuk Res. 2008 Apr; 32(4):553-8.
Score: 0.013
-
Ross RW, Halabi S, Ou SS, Rajeshkumar BR, Woda BA, Vogelzang NJ, Small EJ, Taplin ME, Kantoff PW. Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study. Clin Cancer Res. 2005 Nov 15; 11(22):8109-13.
Score: 0.011
-
Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol. 2003 Jul 15; 21(14):2673-8.
Score: 0.009